Guardian Pharmacy Services (NYSE:GRDN) Posts Earnings Results, Misses Estimates By $0.04 EPS

Key Points

• Guardian Pharmacy Services reported $0.18 earnings per share (EPS) for the quarter, missing analysts' expectations of $0.22 by $0.04.
• The company's stock declined by 0.7% during trading, reaching a price of $19.84.
• Insiders sold over 11 million shares of the company stock in recent months, amounting to approximately $228.7 million.

Guardian Pharmacy Services (NYSE:GRDN - Get Free Report) announced its quarterly earnings data on Monday. The company reported $0.18 earnings per share for the quarter, missing analysts' consensus estimates of $0.22 by ($0.04), Zacks reports. The firm had revenue of $344.33 million for the quarter, compared to analysts' expectations of $329.57 million. Guardian Pharmacy Services had a negative net margin of 6.90% and a negative return on equity of 52.41%. Guardian Pharmacy Services updated its FY 2025 guidance to EPS.

Guardian Pharmacy Services Price Performance

NYSE GRDN traded down $0.41 during trading hours on Friday, reaching $23.48. The company's stock had a trading volume of 9,046 shares, compared to its average volume of 161,631. The firm has a market capitalization of $1.49 billion and a price-to-earnings ratio of -15.50. Guardian Pharmacy Services has a 1-year low of $14.16 and a 1-year high of $26.91. The company's 50-day moving average is $20.68 and its two-hundred day moving average is $21.49.

Insider Buying and Selling

In related news, Director William E. Bindley sold 3,508,905 shares of the company's stock in a transaction dated Tuesday, May 27th. The stock was sold at an average price of $20.16, for a total value of $70,739,524.80. Following the completion of the transaction, the director owned 2,591,271 shares of the company's stock, valued at approximately $52,240,023.36. This represents a 57.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Fred Burke sold 747,102 shares of the stock in a transaction that occurred on Tuesday, May 27th. The shares were sold at an average price of $20.16, for a total value of $15,061,576.32. Following the transaction, the insider directly owned 551,724 shares of the company's stock, valued at $11,122,755.84. The trade was a 57.52% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 11,344,912 shares of company stock worth $228,713,426 in the last ninety days. 63.71% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in GRDN. Dynamic Technology Lab Private Ltd purchased a new position in shares of Guardian Pharmacy Services during the first quarter worth $233,000. JPMorgan Chase & Co. raised its stake in shares of Guardian Pharmacy Services by 48.0% in the second quarter. JPMorgan Chase & Co. now owns 6,027 shares of the company's stock valued at $128,000 after acquiring an additional 1,956 shares in the last quarter. Legal & General Group Plc raised its stake in shares of Guardian Pharmacy Services by 1,783.1% in the second quarter. Legal & General Group Plc now owns 14,895 shares of the company's stock valued at $317,000 after acquiring an additional 14,104 shares in the last quarter. Rhumbline Advisers raised its stake in Guardian Pharmacy Services by 121.1% in the second quarter. Rhumbline Advisers now owns 16,174 shares of the company's stock valued at $345,000 after buying an additional 8,860 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new stake in Guardian Pharmacy Services in the second quarter valued at $214,000.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on GRDN. Wall Street Zen downgraded Guardian Pharmacy Services from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. Truist Financial reaffirmed a "buy" rating and set a $28.00 target price (up from $25.00) on shares of Guardian Pharmacy Services in a research report on Monday, May 19th. Finally, Raymond James Financial set a $28.00 target price on Guardian Pharmacy Services and gave the stock an "outperform" rating in a research note on Wednesday, May 14th.

Guardian Pharmacy Services Company Profile

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes.